Health Condition 1: N944- Primary dysmenorrhea
Conditions
Interventions
Intervention1: Abhal (J.communis L.): Orally 1.5g will be given thrice a day from day 1 to day 3 of menstruation for 2 consecutive months
Control Intervention1: Mefenamic acid: 250 mg capsule of mefen
Sponsors
National Institute of Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: Women aged from 18 to 35 years with a history of regular menstrual cycle (28 ±7 days) with primary dysmenorrhoea .6 Having experienced menstrual pain of intensity from moderate to severe and the Visual Analog Scale >¬4cm for at least three menstrual cycles before this study.6 Primary dysmenorrhoea with or without associated symptoms like headache, dizziness, fever, nausea, vomiting, diarrhoea and fatigue.
Exclusion criteria
Exclusion criteria: Patient with secondary dysmenorrhoea, heavy menstrual bleeding and irregular menstrual cycles. Patient with malignancies. Patient taking OCPs6 and using intrauterine devices. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in VAS Scale for pain intensityTimepoint: Once every month during treatment for three months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Health-related quality life assesses by SF12 Questionnaire and Change in uterine artery blood flow parameters (PI, RI and S/D ratio)Timepoint: At third month | — |
Countries
India
Contacts
Public ContactArshiya Sultana
National Institute of Unani Medicine
Outcome results
None listed